

A Comprehensive Review: Drug Interactions and Polypharmacy

Dua Fatima¹, Faiza Waseem¹, Nadia Iqbal^{2*}, Tehseen Riaz¹, Irfan Bashir¹, Tooba Mehboob¹

¹Faculty of pharmacy, University of central Punjab, Lahore, Pakistan

²Department of Biochemistry and Biotechnology, The Women University, Multan

*Corresponding email: naaaadia7@gmail.com

Abstract:

The aim of our study is to identify the drug interactions due to polypharmacy. A medication interaction happens when the impact of one medication is changed in the presence of other. The effect of interfacing drugs can be controlled securely without causing any harm to the patient through cautious checking and dose change. Polypharmacy is portrayed as "the utilization of various medicines or potentially the combination of a greater number of prescriptions that are clinically prescribed, leading to superfluous medication use. Polypharmacy includes the number of medicines taken by the patient, the provision of at least one wrong medicine, or a combination of both, which can expand the danger for adverse medication occasions, underutilization of drug, and redundancy of medication. Polypharmacy Management is an entire framework approach that upgrades the consideration of multimorbid patients through amplifying advantage while decreasing the dangers of improper polypharmacy. The review and assessment of prescription is an intercession that should be ordinarily performed by clinical drug specialists to improve the drug therapy results, medicine's adverse impact and guaranteed the use of ideal prescription. There should be a proper and strong role and communication of physicians, pharmacists, and patients in society, especially in developing countries. The potential risk factors should be identified, like the interaction of diet with the drug therapy so that adverse reactions can be identified and avoided.

Keywords: Polypharmacy; Polymorbidities; Dadar Method; Drug Interaction

1. Introduction

A medication interaction happens when the impact of one medication is changed by the presence of another. Interactions that disturb the retention, dispersion, digestion or elimination of medication are called 'pharmacokinetic' and interactions that change the activity of medication are called 'pharmacodynamic'. Medication interactions can enhance the impact of medication, increase harmfulness. In some cases, it may reduce the impacts of a medication, resulting in diminished viability or treatment disappointment. Many interfacing drugs can be controlled securely without making any harm to the patient through cautious checking and dose change.

1.1. Types of drug interaction

1.1.1. Drug-drug interactions

Unfavorable drug drug interactions (DDIs) are brought about by pharmacological co-administration of medications. This type of interaction results in dismalness, mortality and causes enormous clinical costs. Medication-related components that expand the risk for clinically huge interactions includes a narrow therapeutic ratio, an assortment of pharmacokinetic impacts, changes for drug retention, hepatic digestion, catalyst induction and inhibition, and renal elimination (Huang et al., 2020). Food

can affect drug retention by physicochemical and physiological alterations (Fleisher et al., 1999).

1.1.2. Drug-disease interactions

Medication morbidity interactions or drug disease interaction (DDIs) are circumstances where the pharmacotherapy used to treat an infection causes deterioration of other sicknesses in patients. Depending upon the patient's attributes, there might be various explanations behind contra-signs, for example, physiological conditions (age, sexual orientation, pregnancy, and so on), excessive touchiness, or an attending infection according to European Commission; U.S. Branch of Health and Human Services Food and Drug Administration (Tongeren et al., 2020).

1.2 Causes of drug interactions

1.2.1 Inappropriate role of pharmacist in counseling

An ongoing report led in Canada indicated that drug specialist had insignificant clinical interventions when it came to passing over drugs, with one of the most well-known barriers for the outpatients being drug interactions (Korenvain et al., 2018).

1.2.2. Inappropriate communication between doctors and patients

Patients have little knowledge with regards to medication reactions, focusing light on how little is conveyed to them by their doctors. The superfluous, unsuitable, or wrong prescriptions have a critical cost, which is additionally intensified by the rising costs of medication in the US (Ramia et al., 2017).

1.3. Polypharmacy

According to World Health Organization (WHO) "The combination of numerous medications at a similar time or the organization of an inordinate number of drugs." Polypharmacy is portrayed as "the utilization of various medications or potentially the combination of a greater number of prescriptions than are clinically prescribed, speaking to superfluous medication use." Polypharmacy includes the number of meds taken by the patient, the provision of at least one wrong meds, or a combination of both, which can expand the danger for adverse medication occasions (ADEs), underutilization of drug, and redundancy of medication (Shrestha et al., 2019). Proper polypharmacy has been recommended for a person under complex conditions like drug usage is required to be enhanced, medications are ordered by the verified person while keeping the personal satisfaction up, improving life span with limiting medication harm. Conversely, hazardous polypharmacy is where different drugs are endorsed improperly, or where the planned advantage of the medicine isn't understood. Risky polypharmacy can be brought about by an absence of verification base treatment, damage exceeding advantage, unsuitable pill trouble, or pointless treatment.

2. Incidence of drug interactions due to problematic polypharmacy

By and large, polypharmacy influences somewhere in the range of 40%-50% of elder patients. It has additionally been accounted for that the ubiquity of polypharmacy (5+ medications) is 44%, and the ubiquity of unnecessary polypharmacy (10+ medications) is 12%. The occurrence rate of polypharmacy is 20 for every 100 men going from 17% in people 65–74 years old to 33% in those ≥ 95 years old. The occurrence rate of immoderate polypharmacy is 8 for every 100 years. It was assessed that 3-5% of adverse drug reactions (ADRs) results from DDIs. In the United states US there was a wide variety in the level of DDI endorsing across emergency clinics, going from 1.05% to 4.92%. For Netherland, the pervasiveness and occurrence pace of potential damages and possibly preventable HARMs stay stable between 2008 and 2013. Moreover, to forestall medication harm

ought to particularly target more mature patients (65 years) since they have four times higher pervasiveness of possible HARMs than the youthful patients (18-64 years) (Lghoul et al., 2020). In China, research outcomes suggested that the co morbidities and co-medication use are lower contrasted with different nations because they avoid visiting a doctor in common ailments, and the pervasiveness of potential DDIs is likewise low (Chen et al., 2020).

In Pakistan, few examinations have assessed DDIs in our patients at an announcing rate from 22.3% to 37.7% (Ahmad et al., 2020). An exploration appeared out of the 800 solutions, 290 have at any rate 1 medication drug interactions (36.25 %) in Saudia Arabia (Ahmad et al., 2020). Practically, 50% of the distinguished interactions recorded were because of the propagation of adverse effects of the co-administered agent (Nusair et al., 2020).

3. Morbidity and mortality rate

Unfavorable medication drug interactions (DDIs) stay the main reason for bleakness and mortality. Distinguishing expected DDIs during them education is basic for patients and society. A few computational models have been proposed for DDI expectation, there are still impediments. One of them is a reticular plan of medication representation n for DDI prognosis is lacking. Secondly, expectations depend on restricted specified information and models are specified by an enormous number of factors, consequently, difficult to decipher (Huang et al., 2020).

3.1. Morbidity prevalence due to polypharmacy

Adverse medication errors (ADE) are among the main sources of expanded morbidity, mortality, and wellbeing costs. It was alarmingly revealed that unfavorable medication errors due to drug interactions and polypharmacy speak to the driving reason for death in the USA (Page et al., 2006). Polypharmacy is frequently occurring due to the purported 'medicine course', which includes the clinician's inability to perceive another clinical occasion as an ADR. In such cases, an extra medication is recommended to treat the unfavorable responses causing adverse effects rather than removing faulty medicine, making an endless loop, and adding further dangers to multi- morbid patients (Ellenbogen et al., 2020). Various components impact the event of ADRs optional to medication–drug interactions, for example, age, renal capacity, and other comorbidities. Furthermore, hereditary variety (genetic makeup) is probably going to play an essential function in the advancement of ADRs. For instance, when just considering hereditary polymorphisms in medications utilizing chemicals (cytochrome P450 2C9 (CYP2C9), CYP2C19, and CYP2D6). In the UK, it is assessed that around 20% of grown-ups are in receipt of at least more than 5 ordinary medications, and more than 1 in 20 grown-ups take about 10 or more normal medications. Comparable examples have been found in other European nations. Different prescription use is unequivocally related to advanced age and morbidity (Payne et al., 2020).

4. Risk factors associated with polypharmacy and drug interactions

The most widely recognized multi-drug therapy is to treat indications of metabolic condition (21%), cardiovascular illnesses (31%) trailed by the contagious sicknesses (24%) and gastrointestinal issues (24%), and the last occurrence of polypharmacy in dermatological sicknesses (1% - 2%), and irresistible illnesses (20%) (Turabian et al., 2020). Different examinations have characterized the utilization of at least 10 unique prescriptions unnecessary polypharmacy/hyper-polypharmacy. Hence, for the current examination, polypharmacy status was ordered into three gatherings:

- Non-polypharmacy –the combination of 1–5 medications

- Polypharmacy –a combination of 6–9 medications
- Hyper-polypharmacy –a combination of ≥ 10 medications (Vegada et al., 2018).

4.1. Risk of ADRs associated with polypharmacy for patients in Intensive Care Units (ICU)

Patients in intensive care units (ICUs) normally have serious and hazardous diseases so they get unpredictable pharmacotherapy with a huge number of various medications. On average, patients in the emergency unit get 15 distinct medications, which puts them in high danger of medication drug interactions. The occurrence of clinically huge medication interactions in tertiary care facility is as high as 54%, though abnormal number of reactions per individual is 1.7. Medication interactions are liable for 5% - 9% of all abnormal medication responses in hospitalized patients. It is additionally realized that drug interactions add to expanded morbidity and mortality of patients in ICUs (Jankovic et al., 2018).

4.2. Dietary factors

Numerous medicines have incredible elements that interact with the human body in an unexpected way and fundamentally affect the way of living and dietary habits. A medication reaction is a circumstance where a substance influences the movement of a medication, for example the impacts are expanded or diminished, or they produce another impact that neither produces all alone. Normally, reactions between drugs ring a bell (drug- drug reaction). Notwithstanding, reactions may likewise exist among medications and food components. Some ordinarily utilized spices, organic products just as liquor may cause disappointment of the treatment up to as that of significant variations in the patient's life. Most of food-drug reactions are brought about by food induced changes in the rate and extent of absorption of the medication. Significant symptoms of eating regimen (food) on medications include variation in assimilation of lipids, high protein and fiber diets.

4.3. Age-related physiological changes in elder patients

Age-related persistent sicknesses, for example, dyslipidemia, hypertension, diabetes, and anxiety typically require the utilization of different medications, a state known as polypharmacy. This alludes to the utilization of numerous medicines and a greater number of drugs than clinically demonstrated. There are certain a pharmacodynamic and pharmacokinetic change in the body with advanced age interacts with different drugs. This prompt changed medication impact expanded exposure to abnormal medication responses (ADRs) and medications regularly showing smaller therapeutic window. More articulated changes in synaptic chemicals, for instance, acetylcholine and dopamine, have been seen in the focal sensory system (CNS) among individuals with dementia and an affiliation has been found between brought down serotonin levels and Alzheimer's illness. There will be interactions with the different combination of psychotropic substances (Sönnerstam et al., 2018).

4.4. In pediatric population

Studies have indicated that 49% of hospitalized pediatric patients have always one drug reaction during their hospital admissions. A few creators have portrayed a relationship between the number of pharmacological reactions and the presence of unfavorable occasions that ranges somewhere in the range of 4.4% and 25%. Other examinations show that the occurrence of side effects associated with DDI is 6%, with 37% of these occasions requiring hospitalization and where 13-75% could be intercepted. Some dangers that impact the DDIs in populaces are particularly age or polypharmacy in addition to the characteristics and quantity of infections analyzed in every patient (Medina et al., 2020). Epilepsy and mental issues are predominantly addressed in pediatric polypharmacy research.

Valproic acid followed via carbamazepine and phenobarbital were the most contemplated prescriptions, which were completely utilized in the treatment of epilepsy. Prescriptions used for mental disorders usually implicated polypharmacy needs optimized medication therapy to avoid the risk of ADRs. The National Survey of Children's Health finds that 18.5% of kids required specialized care for abnormalities characterized as progressing or constant ailments that enhance their expectancy of pharmaceutical care for 1 year or more. As special children usually have morbidities, their therapy combinations have regularly not been considered. Oftentimes, meds are utilized off-mark, or utilized for diseases in which they have not been contemplated and affirmed by FDA (Horace et al., 2020).

4.5. Morbidity and polypharmacy

An examination uncovered the presence of methodical relationship among ongoing illnesses and administered drugs in the males and females equal to or more than 65 years old, indicating that they may happen at all ages, including youngsters, and that they have a deeply rooted development. Six examples of morbidity and polypharmacy were recognized, named respiratory, psychologically, cardiometabolic, endocrinological, other-metabolic, and muscle pain. Improper polypharmacy expands the danger of pointless medication use, potential medication interactions and medication sickness reactions and abnormal medication responses (ADRs) (Menditto et al., 2019).

5. Management of polypharmacy and drug interactions

In 2017, the third Global Patient Security Challenge was dispatched by World Health Organization (WHO), Medication without Harm, with a synopsis focus on worldwide wellbeing frameworks to diminish the potential adverse reactions. Polypharmacy Management is an entire framework approach that upgrades the consideration of multimorbid patients through amplifying advantage while decreasing the dangers of improper polypharmacy (Minshull et al., 2019).

5.1 Medication review by pharmacist

Prescription review and assessment is an intercession, ordinarily performed by clinical drug specialists to improve medicine harmlessness and drug therapy results, and guarantee ideal prescription use. It includes the basic assessment of an individual patient's meds to recognize and resolve prescription-related issues, including contraindicated medications. The British Columbia Ministry of Health and Vancouver Coastal Health Authority co-supported a compensation for-execution quality improvement program called the Adverse Drug Event Screening Program, in 2011. Its point was to conduct medication analysis by pharmacists right on time in-emergency clinics for high-hazard patients to guarantee appropriate diagnosis and treatment to avoid problematic polypharmacy (Hohl et al., 2017).

5.2 Training of physician

An especially significant issue in assessing the suitability of recommending drugs in the older is that various prescriptions might be properly shown for one patient with numerous co morbidities. As a rule, just the doctor is familiar with the patient's clinical analyses and their relative seriousness, the patient's ability for understanding the instructions, and other clinical issues. For doctor's consideration, there is a need to bring issues to light regarding dangers of polypharmacy and to instruct them concerning the assessment and conduction of appropriate polypharmacy in the older using clinical practice rules. The medical care framework ought to likewise try to help doctors in essential medicine regulations and encourage prescription survey by giving them drug information on their patients who are taking more than 5 medicines (Fillit et al., 1999).

5.3 Healthcare technology in managing polypharmacy

Risk Prediction tools are one of the techniques in patients with polypharmacy for evaluating the danger of undesired medication responses. An efficient audit distributed in 2014 assessed the nature of hazard expectation instruments for undesired medication responses in individuals more than 65 years old (Molokhia et al., 2017).

5.4 Patient centered education

To address problems related to multiple medicines, we commend that clinicians would profit by the expansion of a patient focused methodology and organized consolidating both clinician and patient viewpoint. This framework is created by the ability of the UK Medicines Information to monitor patient, characterize setting and objectives, recognize medications with likely dangers, evaluate dangers and advantages for one patient therapy with multiple drugs, activities to diminish, pause and proceed with medications use, collaboration with other medical services gives and screen consistently (Barnett et al., 2016).

5.5 Medication review with follow up

There is a procedure for Medical review with follow-up (MRF), the Dadar method (presented as Figure 1); including three phases: Evaluation of patient, Pharmaceutical care plan & Follow up.

5.6 National health service guidelines for medication review

National Health Service, UK proposed guidelines to reduce polypharmacy. The steps involved for reducing polypharmacy are given as Figure 2. The guidelines target to all the health care professionals including prescribers, pharmacist, nurses and policy makers and patients (Maire and Jason et al., 2018)

Acquiring patient information through interview and open questions through Assessment form

The formation of the evaluation structure makes up the center of the Dadar Method.

A treatment (the given arrangement of prescriptions for a medical issue) is viewed as essential on the off chance that it has been intentionally recommended by a prescriber for a medical issue distinguished in the patient.

A treatment (the given arrangement of prescriptions for a medical condition) is viewed as compelling in the event that it adequately controls the medical issue for which it was recommended.

A prescription is viewed as protected in the event that it doesn't cause or destabilize a medical condition in the patient.

Intervention

The "activity that emerges from a previous choice and one which intends to adjust a specific trait of the patient that is utilizing it, or the conditions where it is encased. There are sure helpful standards for organizing modifications

Those representing a genuine danger for the patient.

Any difficult that could be addressed quickly, picked out from the entire arrangement of issues concerning the patient or drug specialist.

Figure 1. Dadar Method

5.6 Pharmacoeconomics

Old age individuals have expanding medical services disbursement. To decrease drug concerning issues and for cost-effectiveness, rules suggest a customary survey of prescription use by clinical medicine review (CMR). An organized basic assessment of patient's drugs with the target of agreeing with the patient about treatment, enhancing the effect of meds, limiting the quantity of ADR's and decreasing the cost of therapy. It has a multidisciplinary approach and the patient, doctor, and drug specialist is included. Clinical pharmacologists could assume a critical part recognizing such efforts. It will also reduce the patient's noxious responses. IVPE uses clinical shreds of evidence to accomplish organizational cost reduction inside the unrestricted economy and for the general public (Serritella et al., 2020).




Figure 2. Steps to reduce polypharmacy

Conclusions and Recommendations

Our study aims to diagnose the gap as like man aging polypharmacy by clinical interventions and reducing the cost of therapy for patients with multi-morbidities. Prescription review and assessment is an intercession that should be performed by clinical drug specialists to improve medicine harmlessness and drug therapy results, and guarantee ideal prescription use. It includes the basic assessment of an individual patient's meds to recognize and resolve prescription-related issues, including contraindicated medications. We still need to work on the enhanced patient compliance suffering from poly-morbidity by modern techniques like the Dadar method. Cost-effectiveness should be the targeted approach of the consultants and pharmacists. There should be a proper and strong role and communication of Physicians, Pharmacists, and Patients in society, especially in developing countries. The potential risk factors should be identified like dietary factors interact with the drug therapy and adverse reactions should be identified and avoided. The use of technology

interactions tracking is important to avoid all kinds of undesirable effects from the multiple drug therapy and dose monitoring is necessary.

References

- Ahmed, N. J., Alamri, S.T., Balaha, M., Al Matrafi, B., Haseeb, A., Hassali M. A., & Khan, A. H. (2020). Evaluation of prescriptions drug-drug interactions in a public hospital in Al-Kharj, Saudi Arabia. *Latin American Journal of Pharmacy*, 39(1), 203-207.
- Barnett, N. L., Oboh, L., & Smith, K. (2016). Patient-centred management of polypharmacy: a process for practice. *European Journal of Hospital Pharmacy*, 23(2), 113-117.
- Chen, R., Chen, J., Tang, Q., Meng, Z., Luo, L., Zhang, W., Deng, A., Zhang, L., Wang, J., Qi, T. Zhang, R., Shen, Y., Liu, L., Steinhart, C. & Lu, H. (2020). Use of comedications and potential drug-drug interactions in people living with HIV in China. *Journal of Infection and Chemotherapy*, 26(7), 722-728.
- Ellenbogen, M. I., Wang, P., Overton, H. N., Fahim, C., Park, A., Bruhn, W. E., Carnahan, L. J., Linsky, A. M., Balogun S. A., & Makary, M. A. (2020). Frequency and predictors of polypharmacy in US Medicare patients: a cross-sectional analysis at the patient and physician levels. *Drugs & aging*, 37(1), 57-65.
- Fillit, H. M., Futterman, R., Orland, B. I., Chim, T., Susnow, L., Picariello, G. P., Scheye, E. C., Spoeri, R. K. Roglieri, J. L. & Warburton, S. W. (1999). Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews. *America Journal of Management Care*, 5(5), 587-94.
- Fleisher, D., Li, C., Zhou, Y., Pao, L. H., & Karim, A. (1999). Drug, meal and formulation interactions influencing drug absorption after oral administration. *Clinical pharmacokinetics*, 36(3), 233-254.
- Hamid, H., Khalid, W., Butt, M. H., Baig, T. H., Naseer, M. S., Mehboob, T. & Tauqeer, H. M. (2020). Incidence, Pattern, and Clinical Characteristics of Potential Drug-Drug Interactions from an Outpatient Department of a Secondary Care Hospital. *Latin American Journal of Pharmacy*, 39(10), 1927-33.
- Hohl, C. M., Partovi, N., Ghement, I., Wickham, M. E., McGrail, K., Reddekopp, L. N., & Sobolev, B. (2017). Impact of early in-hospital medication review by clinical pharmacists on health services utilization. *PLoS one*, 12(2), 1-13.
- Horace, A. E., Golchin, N., Knight, E. M. P., Dawson, N. V., Ma, X., Feinstein, J. A., Johnson, H. K., Kleinman, L. & Bakaki, P. M. (2020). A scoping review of medications studied in pediatric polypharmacy research. *Pediatric Drugs*, 22(1), 85-94.
- Huang, K., Xiao, C., Hoang, T., Glass, L., & Sun, J. (2020). Caster: Predicting drug interactions with chemical substructure representation. In *Proceedings of the AAAI Conference on Artificial Intelligence*, 34(1), 702-709.
- Janković, S. M., Pejčić, A. V., Milosavljević, M. N., Opančina, V. D., Pešić, N. V., Nedeljković, T. T., & Babić, G. M. (2018). Risk factors for potential drug-drug interactions in intensive care unit patients. *Journal of critical care*, 43, 1-6.
- Korenvain, C., MacKeigan, L., Dainty, K., Guilcher, S. J., & McCarthy, L. (2018). Exploring deprescribing opportunities for community pharmacists: protocol for a qualitative study. *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada*, 151(4), 228-232.
- Lghoul-Oulad Saïd, F., Hek, K., Flinterman, L. E., Herings, R. M., Warlé-van Herwaarden, M. F., de Bie, S., ... & van den Bemt, P. M. (2020). Prevalence and incidence rate of hospital admissions related to medication between 2008 and 2013 in The Netherlands. *Pharmacoepidemiology and drug safety*, 29(12), 1659-1668.
- Lima, E. D. C., Camarinha, B. D., Ferreira Bezerra, N. C., Panisset, A. G., Belmino de Souza, R., Silva, M. T., & Lopes, L. C. (2020). Severe Potential Drug-Drug Interactions and the Increased Length of Stay of Children in Intensive Care Unit. *Frontiers in Pharmacology*, 11, 555407.

- Medina-Barajas, F., Vázquez-Méndez, E., Pérez-Guerrero, E. E., Sánchez-López, V. A., Hernández-Cañaveral, I. I., & Huerta-Olvera, S. G. (2020). Pilot study: evaluation of potential drug–drug interactions in hospitalized pediatric patients. *Pediatrics & Neonatology*, *61*(3), 279-289.
- Menditto, E., Gimeno Miguel, A., Moreno Juste, A., Poblador Plou, B., Aza Pascual-Salcedo, M., Orlando, V., Rubio, F. G. & Prados Torres, A. (2019). Patterns of multimorbidity and polypharmacy in young and adult population: Systematic associations among chronic diseases and drugs using factor analysis. *PLoS One*, *14*(2), e0210701.
- Minshull, J., & Barnett, N. (2020). Managing polypharmacy: teamwork in general practice. *Prescriber*, *31*(1), 25-29.
- Molokhia, M., & Majeed, A. (2017). Current and future perspectives on the management of polypharmacy. *BMC Family Practice*, *18*(1), 1-9.
- Nusair, M. B., Al-Azzam, S. I., Arabyat, R. M., Amawi, H. A., Alzoubi, K. H., & Rabah, A. A. (2020). The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan. *Saudi Pharmaceutical Journal*, *28*(2), 155-160.
- Page II, R. L., & Ruscin, J. M. (2006). The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. *The American journal of geriatric pharmacotherapy*, *4*(4), 297-305.
- Payne, R. A. (2020). Polypharmacy and deprescribing. *Medicine*, *48*(7), 468-471.
- Pharmaceutical Care Research Group. (2006). Pharmacotherapy follow-up: The Dader method (3rd revision: 2005). *Pharmacy Practice*, *4*(1), 44-53.
- Ramia, E., Zeenny, R. M., Hallit, S., & Salameh, P. (2017). Assessment of patients' knowledge and practices regarding their medication use and risks in Lebanon. *International Journal of Clinical Pharmacy*, *39*(5), 1084-1094.
- Rodrigues, M. C. S., & Oliveira, C. D. (2016). Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review. *Revista latino-americana de enfermagem*, *24*, e2800.
- Serritella, A. V., Strohbehn, G. W., Goldstein, D. A., Lichter, A. S., & Ratain, M. J. (2020). Interventional pharmacoeconomics: a novel mechanism for unlocking value. *Clinical Pharmacology & Therapeutics*, *108*(3), 487-493.
- Shrestha, S., Shrestha, S., & Khanal, S. (2019). Polypharmacy in elderly cancer patients: Challenges and the way clinical pharmacists can contribute in resource-limited settings. *Aging Medicine*, *2*(1), 42-49.
- Sönnerstam, E., Sjölander, M., Lövheim, H., & Gustafsson, M. (2018). Clinically relevant drug–drug interactions among elderly people with dementia. *European journal of clinical pharmacology*, *74*(10), 1351-1360.
- van Tongeren, J. M., Harkes-Idzinga, S. F., van der Sijs, H., Atiqi, R., van den Bemt, B. J., Draijer, L. W., Hiel, D., Kerremans, A., Kremers, B., de Leeuw, M., Olthoff M. V., Pham, T.K.L., Valentijn-Robertz, R., Tsoi, K., Wichers, I., de Wit, M. & Borgsteede, S. D. (2020). The development of practice recommendations for drug-disease interactions by literature review and expert opinion. *Frontiers in pharmacology*, *11*, 707.
- Turabian, J. L. (2020). Implications on mental health by the coronavirus disease 2019 (COVID-19) pandemic: The role of general practitioner. *Health*, *7*(8), 35-41.
- Vegada, B. N., Shah, A. M., Shah, D., Mogal, K., Santoki, H., & Joshi, R. (2020). Polypharmacy and potential drug-drug interactions among geriatric patients. *National Journal of Physiology, Pharmacy and Pharmacology*, *10*(5).